<DOC>
	<DOCNO>NCT01500915</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy combine fixed-interval pro nata ( PRN ) regimens ranibizumab ( FUSION regimen ) treatment exudative age-related macular degeneration ( AMD ) patient good visual acuity ( VA ) baseline . To establish whether similar efficacy monthly regimen achieve few injection , even patient good VA .</brief_summary>
	<brief_title>FUSION Regimen : Combined Pro Nata Fixed Regimen Ranibizumab Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description>This prospective , open-label , consecutive interventional case series treatment-naïve patient exudative AMD . A loading phase 2-3 injection follow fixed-interval regimen injection combine pro nata regimen 12 month . Endpoints include VA , presence fluid spectral domain optical coherent tomography ( SD-OCT ) , adverse event number injection administer .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>subfoveal juxtafoveal CNV owe AMD , define fluorescein angiography ( FA ) presence SDOCT subretinal intraretinal fluid associate macular edema Best correct visual acuity ( BCVA ) study eye 20/20 20/125 , inclusive total area lesion ( include blood , neovascularization scar/atrophy ) ≤8 disc area , least 50 % must active choroidal neovascularization ( CNV ) ( define neovascular component lesion define FA angiographic subtypes [ predominantly classic , minimally classic occult ] eligible ) clear ocular medium adequate pupillary dilatation allow collection fundus photograph FA sufficient quality analyze intraocular pressure 21 mmHg less previous treatment AMD presence scar atrophy &gt; 75 % total lesion size ( patient subfoveal scar atrophy exclude ) subretinal haemorrhage &gt; 75 % total lesion size ; presence serous retinal pigment epithelial detachment &gt; 5 disc area presence intraocular inflammation ( ≥ trace cell flare ) , epiretinal membrane , macular hole vitreous haemorrhage history idiopathic autoimmuneassociated uveitis either eye significant medium opacity , include cataract , might interfere VA , assessment toxicity fundus photography study eye presence cause CNV , include pathological myopia ( spherical equivalent 3 diopter , axial length 25 mm , fundus finding suggestive pathologic myopia ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture multifocal choroiditis retinal treatment ( aside antioxidant ) , include ( limited ) intravitreal injection , photodynamic therapy verteporfin , laser photocoagulation surgery history rhegmatogenous retinal detachment , par plana vitrectomy corneal transplant previous radiation region study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>AMD</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>antiVEGF</keyword>
	<keyword>regimen injection</keyword>
	<keyword>anti VEGF regimen</keyword>
	<keyword>PRN</keyword>
	<keyword>treat extend</keyword>
</DOC>